Latest Janssen Biotech Inc. Stories
SAN DIEGO, March 10, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.
CCFA, AGA and Janssen Biotech Announce New Grant Program NEW YORK, Feb.
Approval represents fourth indication for IMBRUVICA in the U.S. HORSHAM, Pa., Jan. 29, 2015 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen") today announced that the U.S.
- First and Only FDA-Approved Treatment for WM Patients SUNNYVALE, Calif., Jan. 29, 2015 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S.
SOUTH SAN FRANCISCO, Calif., Jan.
-- Collaboration Combines Isis' RNA-Targeted Technology With Expertise of Janssen in Autoimmune Disorders and Therapeutic Formulation -- CARLSBAD, Calif., Jan.
SAN DIEGO, Dec. 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months SAN FRANCISCO and RARITAN, N.J.,
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.